Multimodular biomarker analysis workflow for Diagnosis, PROgnosis and MONitoring of drug treatment response in bladder cancer (http://www.surrey.ac.uk/dipromon/index.htm)
The DIPROMON platform will allow design of a novel patient stratification concept, building the tools, technologies and procedures to apply this concept to the bladder cancer patient scenario. The final stage will be validating the concept in patients with bladder cancer.
The role of LIONEX in Dirpomon is to discover, characterise and produce purified biomarkers for test development.
University of Surrey
Prof Hardev Pandha email@example.com
Emergentec biodevelopment GmbH
AXO Science SAS
Dr Christophe Marquette firstname.lastname@example.org
Austrian Institute of Technology GmbH
Claudia Preininger email@example.com
Gottfried Koehler firstname.lastname@example.org